Navigation Links
New Guidelines Issued on Hormone Receptor Testing for Breast Cancer
Date:4/20/2010

Up to 20% of current results may be inaccurate, study says

TUESDAY, April 20 (HealthDay News) -- The American Society of Clinical Oncology and the College of American Pathologists have issued new guidelines to improve the accuracy of the testing of estrogen and progesterone receptors in breast cancer patients.

The growth of as many as two-thirds of breast cancers are thought to be affected by the action of the estrogen-receptor pathway.

Estrogen (ER) and progesterone receptor (PgR) testing allows doctors to determine whether a patient's breast cancer fits into that group. In that case, the patient may be eligible to be treated with so-called endrocrine therapies -- including the drug tamoxifen -- that can improve survival.

But there's a problem: Worldwide, as many as 10 percent to 20 percent of these screens, known as immunohistochemistry tests, may be wrong.

"There is clearly a need to accurately identify breast cancer subtypes as ER- and/or PgR-positive to help us identify those patients most likely to benefit from endocrine therapy and minimize the risk of potentially denying effective and lifesaving therapy to patients incorrectly labeled as having ER/PgR-negative invasive disease, while allowing patients with true ER/PgR-negative disease to be considered for other therapies," Dr. Antonio C. Wolff, co-chair of a joint panel on hormone receptor testing in breast cancer and a professor of oncology at Johns Hopkins Kimmel Cancer Center in Baltimore, said in a news release.

Among a long list of recommendations, the guidelines encourage regular testing in newly diagnosed invasive breast cancers, uniform testing procedures and validation of tests.

The new guidelines were published April 19 in the Journal of Clinical Oncology and the Archives of Pathology & Laboratory Medicine.

More information

For more on breast cancer, see the U.S. National Library of Medicine.



-- Randy Dotinga



SOURCE: American Society of Clinical Oncology, news release, April 19, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. NICE guidelines ration affordable osteoporosis drugs
2. Sunquest Information Systems Supports New Meaningful Use Guidelines for Laboratories Transferring H1N1 Results
3. ASTRO, ACR issue IGRT, SBRT guidelines
4. Jefferson neurosurgeon helps draft new treatment guidelines for brain metastases
5. Change in mammography guidelines questioned
6. Milliman Care Guidelines Offers Online Interrater Reliability Tool and Training
7. New Guidelines Suggest Botox for Cerebral Palsy
8. NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy
9. ASGE issues guidelines on management of antithrombotic agents for endoscopic procedures
10. New Guidelines Urge A1C Test for Diabetes Diagnosis
11. Fewer headaches on the horizon thanks to latest guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: